Allied Market Research recently published a report, titled, “Ankylosing Spondylitis Market by Drug Class (NSAIDs, TNF Inhibitors and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021–2030.” As per the report, the global ankylosing spondylitis industry was accounted for $5.14 billion in 2020, and is expected to reach $8.11 billion by 2030, growing at a CAGR of 4.6% from 2021 to 2030.
Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a type of arthritis, in which spine bones grow or fuse together, causing the spine to become rigid. Symptoms of ankylosing spondylitis include pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.
For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/10631
Covid-19 scenario –
- The outbreak of covid-19 impacted the ankylosing spondylitis market. Due to the medical emergency during the first and second wave of the pandemic, hospitals were struggling to manage and treat huge number of covid patients with limited capacity. Thus, many surgeries were postponed.
- As there was high risk of spreading of covid infections many orthopedic surgeries were canceled or postponed.
The cause of ankylosing spondylitis is not discovered yet, however it has been linked with a gene called HLA-B27. It has been observed that some patients are carrying same gene i.e. HLA-B27. Ankylosing spondylitis can be diagnosed via X-rays of the back and pelvis; or by physical examination
By Region.
| · North America (U.S., Canada, Mexico)
· Europe (Germany, France, UK, Italy, Spain, Rest of Europe) · Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia Pacific) · LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA) |
Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/10631
Key players-
- Eli Lilly and Company
- AbbVie, Inc,
- Gilead Sciences
- Amgen, Inc,
- Merck & Co. Inc
- UCB, Inc.,
- Pfizer, Inc
- Janssen Pharmaceuticals
- Reliance Life Sciences Pvt. Ltd
- Novartis AG
On the basis of drug class, the market is divided into NSAIDs, TNF inhibitors and others. The NSAIDs segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in number patients suffering from ankylosing spondylitis and high reliability of product.
By distribution channel market is divided into hospitals pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominates the ankylosing spondylitis market in 2020, and this trend is expected to continue during the forecast period, and high prevalence of ankylosing spondylitis.
North America accounted for a majority of the global ankylosing spondylitis market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in number of ankylosing spondylitis patients.
FREQUENTLY ASKED QUESTIONS?
Q1. What is the total market value of Ankylosing spondylitis market report ?
Q2. What would be forecast period in the market report?
Q3. What is the market value of Ankylosing spondylitis market in 2021?
Q4. Which is base year calculated in the Ankylosing spondylitis market report?
Q5. Does the ankylosing spondylitis company is profiled in the report?
Q6. Which are the top companies hold the market share in Ankylosing spondylitis market?
Q7. What are the market values / growth % of emerging countries?
Q8. What are the key trends in the Ankylosing spondylitis market report?